The regulatory landscape governing US-China biotech transactions is evolving rapidly on both sides of the Pacific. Multiple legislative proposals, executive actions, and administrative rulemakings are proceeding in parallel, each at different stages of maturity and each subject to significant political uncertainty. While the proposals discussed in this LawFlash should not
US-China biotech transactions: Navigating each country’s evolving regulatory landscape
Several legislative proposals, actions, and regulations are underway in parallel, all at different stages of maturity and all subject to significant political uncertainty.